Drug
Catequentinib hydrochloride clinical trials
Also written Anlotinib Hydrochloride and AL3818.
- studies test it
- 93
- open now
- 19
- in phase 3
- 13
- first study started
- 2018
Keep track of what changes. Save the catequentinib hydrochloride studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
93 studies that test it; most in 2019 (22)
| Year | Studies |
|---|---|
| 2018 | 9 |
| 2019 | 22 |
| 2020 | 16 |
| 2021 | 18 |
| 2022 | 10 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 11
- Phase 2
- 62
- Phase 3
- 13
- Phase 4
- 5
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (21) · Sun Yat-sen University (5) · Peking Union Medical College Hospital (4) · Zhejiang Cancer Hospital (4) · The First Affiliated Hospital with Nanjing Medical University (3) · Henan Cancer Hospital (3) · Fudan University (2) · Akeso (2)
Often tested with
Tested in the same studies.
Penpulimab (13) · Benmelstobart (12) · Docetaxel (5) · Etoposide (4) · Toripalimab (3) · Cisplatin (3) · Oxaliplatin (2) · Tislelizumab (2)
Studies
Open first, then newest update. How each study uses catequentinib hydrochloride is read from its arms, and is right about nine times in ten.
Testing it · 93
- A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07358676Written as Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy
- Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial NephrectomyNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07627464Written as Anlotinib hydrochloride + Benmelstobart + Partial nephrectomy
- Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）RecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05167994Written as Anlotinib hydrochloride
- Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07385079Written as Anlotinib Hydrochloride Capsules
- Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLCRecruitingPhase 2Ji YonglingNCT06379087Written as Anlotinib Hydrochloride Capsule
- Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial CancerNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06475599Written as Anlotinib hydrochloride capsule + TQB2450 injection
- SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung CancerRecruitingNot applicableThe First People's Hospital of LianyungangNCT06476093Written as Anlotinib hydrochloride
- A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLRecruitingPhase 2Zhejiang Cancer HospitalNCT06086197Written as Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
- A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.RecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06010901Written as Anlotinib hydrochloride capsules
- XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05494060Written as Anlotinib hydrochloride capsule
- Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid CancerNot yet recruitingNot applicablePeking Union Medical College HospitalNCT06062563Written as Anlotinib Hydrochloride Capsule and Penpulimab
- Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal CarcinomaNot yet recruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT05996484Written as Anlotinib hydrochloride
- Study of Anlotinib in Patients With Advanced Medullary Thyroid CarcinomaRecruitingPhase 4Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05830500Written as Anlotinib Hydrochloride Capsule
- A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and ChemotherapyRecruitingPhase 1Jinming YuNCT05942508Written as TQB2450 Injection + Anlotinib Hydrochloride Capsules
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05913089Written as TQB2450 injection + Anlotinib Hydrochloride Capsule
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05862337Written as Anlotinib hydrochloride capsules, Penpulimab injection
- TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Not yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05718167Written as Anlotinib hydrochloride capsule
- Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma PatientsRecruitingPhase 2Jiangxi Provincial Cancer HospitalNCT05252078Written as Anlotinib hydrochloride
- Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable MelanomaNot yet recruitingPhase 1/2Xijing HospitalNCT05539118Written as Anlotinib hydrochloride
- Anlotinib Maintenance Treatment for Advanced Soft Tissue SarcomaCompletedPhase 2Sun Yat-sen UniversityNCT03890068Written as Anlotinib Hydrochloride
See all 93 studies that test catequentinib hydrochloride →
Given in every arm · 7 — catequentinib hydrochloride is usual care beside what is tested
- Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)RecruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07165951Written as Anlotinib Hydrochloride Capsules
- A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade ChondrosarcomaRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05193188Written as Anlotinib hydrochloride
- A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic CarcinomaTerminatedPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT05193604Written as Anlotinib Hydrochloride Capsule
- A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue SarcomaStatus unknownPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05121350Written as Anlotinib hydrochloride capsule
- To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal CancerStatus unknownPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05198531Written as Anlotinib Hydrochloride Capsule
- Novel Treatment of Advanced Hepatocellular CarcinomaStatus unknownPhase 3The First Affiliated Hospital of Zhengzhou UniversityNCT03950518Written as Anlotinib Hydrochloride Capsules
- Treatment of Advanced Intrahepatic CholangiocarcinomaStatus unknownPhase 3The First Affiliated Hospital of Zhengzhou UniversityNCT03940378Written as Anlotinib Hydrochloride Capsules
Codes
What other systems call catequentinib hydrochloride · ClinicalTrials.gg INT015954
- UNII (FDA) A3749M6582CATEQUENTINIB HYDROCHLORIDEOne source FDA
- NCI Thesaurus C106428Catequentinib HydrochlorideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | A3749M6582 | CATEQUENTINIB HYDROCHLORIDE | One source FDA |
| NCI Thesaurus | C106428 | Catequentinib Hydrochloride | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.